Clinical evidence shows that also patients without BRCA mutation or homologous recombination deficiency (HRD) could benefit from PARP inhibitors and this might not be limited to the maintenance setting48,50. This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.